NGL Fine-Chem Limited (NSE:NGLFINE)
3,055.60
+10.20 (0.33%)
Jun 19, 2026, 3:29 PM IST
NGL Fine-Chem Revenue
In the fiscal year ending March 31, 2026, NGL Fine-Chem had annual revenue of 5.01B INR with 36.03% growth. NGL Fine-Chem had revenue of 1.49B in the quarter ending March 31, 2026, with 57.22% growth.
Revenue
5.01B
Revenue Growth
+36.03%
P/S Ratio
3.79
Revenue / Employee
9.63M
Employees
520
Market Cap
18.99B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2026 | 5.01B | 1.33B | 36.03% |
| Mar 31, 2025 | 3.68B | 295.68M | 8.73% |
| Mar 31, 2024 | 3.39B | 606.08M | 21.79% |
| Mar 31, 2023 | 2.78B | -394.22M | -12.42% |
| Mar 31, 2022 | 3.18B | 595.28M | 23.08% |
| Mar 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Sun Pharmaceutical Industries | 584.62B |
| Cipla | 278.28B |
| Apollo Hospitals Enterprise | 252.29B |
| Divi's Laboratories | 105.60B |
| Indoco Remedies | 18.45B |
| Shalby | 11.41B |
| Windlas Biotech | 9.04B |
| Krsnaa Diagnostics | 7.99B |